Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityT Cell Responses To TumorsTumor ImmunopathologyTumor-infiltrating LymphocytesT-cell Responses To Tumor AntigensTh1 Effector FunctionTh1 Immune ResponseTh1 ResponsesTh1 Th2 BalanceTumor ImmunogenicityTumor-host Immune Interactions
To investigate the precise role of antigen-specific Th1 and Th2 cells in tumor immunity, we developed a novel adoptive tumor-immunotherapy model using OVA-specific Th1 and Th2 cells and an OVA gene-transfected tumor. This therapeutic model demonstrated that both antigen-specific Th1 and Th2 cells had strong antitumor activity in vivo with distinct mechanisms. However, immunological memory suitable for the generation of tumor-specific cytotoxic T lymphocytes was induced only when tumor-bearing mice received Th1 cell therapy, but not Th2 cell therapy. Thus it was strongly suggested that Th1-dominant immunity is critically important for the induction of antitumor cellular immunity in vivo. We also proposed that several immunomodulating protocols using interleukin (IL)-12, IL-12 gene, the natural killer T cell ligand alpha-galactosylceramide, or Th1 cytokine-conditioned dendritic cells might be useful strategies for the induction of Th1-dominant immunity essential for the development of tumor-specific immunotherapy.
7
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Murine interleukin-4 displays potent anti-tumor activity in vivo
Robert I. Tepper, Paul K. Pattengale, Philip Leder · Cell · 1989 · 780 citations
Medicine, Immunology, Oncology +10
Gideon Strassmann, Chaim O. Jacob, Rick L. Evans et al. · The Journal of Immunology · 1992 · 112 citations · Full text
Life Sciences, Immunology, Oncology +17